Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.

BMC Neurol. 2016 Jul 12;16:98. doi: 10.1186/s12883-016-0625-0.

2.

[Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].

Hartung HP, Haas J, Meergans M, Tracik F, Ortler S.

Nervenarzt. 2013 Jun;84(6):679-704. doi: 10.1007/s00115-013-3781-0. Review. German.

PMID:
23669866
3.

[Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval].

Haas J, Linker RA, Hartung HP, Meergans M, Ortler S, Tracik F.

Nervenarzt. 2012 Dec;83(12):1575-81. doi: 10.1007/s00115-012-3612-8. German.

PMID:
23203160
4.

Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.

Mäurer M, Ortler S, Baier M, Meergans M, Scherer P, Hofmann W, Tracik F.

Mult Scler. 2013 Apr;19(5):631-8. doi: 10.1177/1352458512463481. Epub 2012 Oct 15.

PMID:
23069874
5.

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators.

N Engl J Med. 2008 Sep 25;359(13):1343-56. doi: 10.1056/NEJMoa0804602. Epub 2008 Sep 2.

6.

Downregulation of beta-adrenergic receptors by low density lipoproteins and its prevention by beta-adrenergic receptor antagonists.

Brehm BR, Meergans M, Axel DI, Pfohl M, Heinle H, Karsch KR.

Cardiovasc Res. 1998 May;38(2):522-30.

PMID:
9709415

Supplemental Content

Loading ...
Support Center